Howard Horn - Mar 1, 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: Chief Financial Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: Mar 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/4/2025, 07:56 PM
Previous filing: Oct 11, 2024
Next filing: Mar 10, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+15.7K	+16.96%	$0.00	108K	Mar 1, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+28.2K		$0.00	28.2K	Mar 1, 2025	Common Stock	28.2K	$42.92	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.